ONAMI funded Tomegavax acquired by Vir Technology, with $600M to Advance Immunotherapy

Essentials of SBIR/STTR Commercialization

Join VertueLab for this Zoom Webinar held from 10:30am - 12:00pm on Wednesday, May 1.

Commercialization and transition plans can be a key differentiator in the SBIR/STTR programs, it is important to know what the agencies are looking for and how to go about developing a good plan.

This session will review the requirements and guide you through where to start, what to include, and how to show your best self. Get tips on developing the components of a credible commercialization plan from demonstrating market opportunity, to product/technology considerations, developing business strategy and building your team. Reviewer exceptions are covered throughout along with agency requirements, and much more.

Webinar registration is now open.